Abstract
We have previously shown that heparin-binding EGF-like growth factor (HB-EGF), a glycoprotein that is naturally present in low levels in human breast milk, protects the intestines from injury in several different animal models, including a model of neonatal necrotizing enterocolitis (NEC). In addition to its trophic effects which are mediated by its ability to stimulate intestinal epithelial cell proliferation and migration, HB-EGF prevents the production of injurious mediators of intestinal injury, and acts as an anti-inflammatory factor. More recently, we have shown that HB-EGF protects intestinal stem cells (ISC) from injury in our animal model of NEC. We believe that the ability of HB-EGF to protect the intestines from NEC may be due, in large part, to its effects on ISC. Ongoing studies in our lab have examined the ability of HB-EGF to act synergistically with transplanted mesenchymal stem cells (MSC) in protection of the intestines from NEC. HB-EGF stimulates MSC proliferation and migration in vitro, and promotes transplanted MSC engraftment into injured intestine in vivo. The administration of both HB-EGF and MSC decrease the incidence and severity of NEC, and increased survival, in our model. In addition, we have recently shown that HB-EGF protects the enteric nervous system from injury, and acts to promote intestinal motility. Collectively, these findings lend further support for the use of HB-EGF in the future as a potential therapy for the prevention or treatment of NEC.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Besner, G., Yang, J., Watkins, D. et al. Heparin-Binding EGF-Like Growth Factor (HB-EGF): Can We Add this to Breast Milk in the Future to Prevent Necrotizing Enterocolitis. Pediatr Res 70 (Suppl 5), 2 (2011). https://doi.org/10.1038/pr.2011.227
Issue Date:
DOI: https://doi.org/10.1038/pr.2011.227